Q1 results for the US and EU have improved. Further improvement needs macro data to progress but trade and geopolitical risks are clear threats.

The Q1 reporting season has improved visibly in the US at the yearly growth of +6% and 3.7% for earnings and sales, respectively. The surprises vs expectations are high, too: 4.6% and +0.36%.

Highlights:

  • The Q1 reporting season has improved visibly in the US at the yearly growth of +6% and 3.7% for earnings and sales, respectively. The surprises vs expectations are high, too: 4.6% and +0.36%.
  • US Q1 earnings estimates’ drop has been massive during the last year, thus helping current beat.
  • EU results are positive, too, showing – for the median sector – an earnings growth of +6% and 3.4% for sales. Surprise vs analysts’ expectations is +4.4% for earnings and +1% for sales.
  • Concerning earnings for European styles, Value and Large caps beat Growth and Small capes.
  • Japanese numbers are weak, mirroring weaker exports and investments.
  • US and EMU revisions are trending better thanks to decent Q1 results and stabilizing macro surprises. But growth estimates for 2020 and 2021 remain sanguine.
  • The stabilization in the macro indicators and, most of all, the reaffirmed dovish stance by central banks supports a positive mid-term outlook for profits.
  • That said, increasing trade and political risks are affecting firms’ confidence, inducing a milder and slower rebound in both macro indicators and earnings versus current expectations: we stay moderately positive into year end on equities, but keeping a rather neutral near-term stance, with risks of further downside correction.

Download the full publication below

Q1 RESULTS FOR THE US AND EU HAVE IMPROVED. FURTHER IMPROVEMENT NEEDS MACRO DATA TO PROGRESS BUT TRADE AND GEOPOLITICAL RISKS ARE CLEAR THREATS.

RELATED INSIGHTS

COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.
INCORPORATING QUANT SIGNALS INTO EU EQUITY SECTOR/STYLE STRATEGY: MAINTAIN A TILT TO CYCLICALS AND VALUE
We present an update of our proprietary equity valuation tool, based on quant models. It provides indications of over- or undervaluation for different sectors and styles of European equities, which is further enriched by our qualitative analysis. Currently, among European equity sectors, financials, energy, telecoms, and autos look undervalued while Pharma, utilities and software appear overvalued.
CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.